Bayer Technology. Bayer agrees to grant, and hereby grants, to Symyx a nonexclusive, royalty-free license under the Bayer Technology to conduct the research activities in the Research Program. Notwithstanding Section 5.1 above, Symyx shall retain the right under the Program Technology to make, have made and use Agreement Compounds for its own research purposes (i.e., to develop, improve and validate its technology and intellectual property).
Bayer Technology. It is contemplated by the parties that Bayer may from time to time, in its discretion, offer Paravax access to certain Bayer proprietary technology which would assist in the development and/or manufacture of the Toxoplasmosis Vaccine. In the event that Bayer is willing to offer access to such technology to Paravax, the parties will negotiate in good faith to reach agreement upon reasonable terms and conditions upon which Paravax may make use of such technology for the development and/or manufacture of the Toxoplasmosis Vaccine.
Bayer Technology. Subject to the terms and conditions set forth in this Agreement, Bayer grants to Micromet a non-exclusive, royalty-free license, under any applicable Patents or Know-How Controlled by Bayer during the [***] of the [***] (including the [***] and Bayer’s interest in the [***]), for the sole purpose of conducting those development responsibilities assigned to Micromet under the [***] Development Plan. Such license will be sublicensable solely to subcontractors approved by Bayer, such approval not be unreasonably withheld. *** Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Bayer Technology. Subject to Section 11.3.5, Bayer shall be solely responsible, as it shall determine in its sole discretion, and shall bear all costs, for Patent Prosecution with respect, in whole or in part, to any Bayer Enabling Technology and Bayer Project Technology. [ * ] Confidential Treatment Requested
Bayer Technology. It is contemplated by the parties that Bayer may from time to time, in its discretion, offer Paravax access to certain Bayer proprietary technology which would assist in the development and/or manufacture of the Canine Heartworm Vaccine. In the event that Bayer is willing to offer access to such technology to Paravax, the parties will negotiate in good faith to reach agreement upon reasonable terms and conditions upon which Paravax may make use of such technology for the development and/or manufacture of the Canine Heartworm Vaccine.
Bayer Technology. Bayer shall own (or control through licenses from Third Parties) all Bayer Technology and, subject to the provisions of this Agreement regarding Collaboration Compound IP, all other Technology of Bayer, whether existing as of the Effective Date or identified or developed during the term of this Agreement or thereafter, made or developed independently by Bayer outside the scope of the Research Program, even if used to support the aims of the Research Program, with the exception of any PROTAC Improvement IP developed by Bayer in the course of the research or development of one or more Collaboration Compounds or Products in the Territory in accordance with the licenses granted under this Agreement that is to be owned by Arvinas as provided in Section 7.1.4 and that, for clarity, is not Sole Bayer PROTAC Improvement IP (with respect to which rights of the Parties shall be governed by Sections 7.1.4(b) and (c)). Nothing in this Agreement shall be deemed to grant Arvinas any rights to own, use or access any Bayer Technology or other Patent Rights or other Technology of Bayer other than as expressly provided in this Agreement.
